Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit

R.E.J. Ryder¹, C. Walton², P.H. Winocour³, ABCD nationwide exenatide audit contributors⁴

1 City Hospital, Birmingham, United Kingdom
2 Hull Royal Infirmary, Hull, United Kingdom
3 Queen Elizabeth II Hospital, Welwyn Garden City
4 numerous other hospitals and diabetes centres, United Kingdom

Safety and efficacy of using exenatide in combination with insulin in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit

B. Jose¹, R.E.J. Ryder¹, K.Y. Thong¹, S. Thozhukat², W. Shafiq², ABCD nationwide exenatide audit contributors

¹City Hospital, Birmingham, UK

²Hull Royal Infirmary, Hull, UK

NICE guidelines versus clinical practice – GLP-1 receptor agonists in type 2 diabetes: the ABCD nationwide audits

KY Thong¹, P Sen Gupta², ML Cul^l2, KA Adamson³, DS Dove⁴, SV Rowles⁵, S Tarpey⁵, C Duncan⁶, J Chalmers⁶, R Harper⁷, P McDonald⁷, U Brennan⁷, C Walton⁸, REJ Ryder² 

¹School of Medicine and Pharmacology University of Western Australia, Perth, Australia

The efficacy of exenatide and liraglutide among South Asians in the Association of British Clinical Diabetologists nationwide audits

K.Y. Thong¹, P. Sen Gupta¹, R.E.J. Ryder¹

¹City Hospital, Diabetes, Birmingham, United Kingdom

Factors associated with HbA1c and weight changes at 6 months in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audit

C. Walton¹, R.E.J. Ryder², M.L. Cull², A.P. Mills², K.Y.Thong²

¹Diabetes, Hull Royal Infirmary, Hull UK

²Diabetes, City Hospital, Birmingham, UK

The Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits

R.E.J. Ryder¹, K.Y. Thong¹, M.L. Cull¹, A.P. Mills¹, C. Walton², ABCD nationwide exenatide and liraglutide audit contributors;

¹Diabetes, Endocrinology and Lipids Metabolism, City Hospital, Birmingham, UK

²Hull Royal Infirmary, Hull,UK

Response of HbA1c and weight against time in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits

Ken Y Thong¹, Bob Ryder¹ on behalf of the ABCD nationwide exenatide and liraglutide audits contributors

¹City Hospital, Birmingham, UK

16.6% (1 in 6) patients who continued insulin at the time of exenatide start came off insulin in the Association of British Clinical Diabetologists (ABCD) Nationwide Exenatide Audit

K.Y. Thong¹, B. Jose¹, N. Sukumar¹, M.L. Cull¹, A.P. Mills¹, T. Sathyapalan², W. Shafiq², A. Rigby², C. Walton², R.E.J. Ryder¹, on behalf of the ABCD nationwide exenatide audit contributors;

¹Diabetes, City Hospital, Birmingham, United Kingdom

Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit

K.Y. Thong¹, R.E.J. Ryder¹, B. Jose¹, T. Sathyapalan², W. Sha!q² , A. Rigby² , C. Walton² , ABCD Nationwide Exenatide Audit Contributors 

¹City Hospital, Birmingham

²Hull Royal In!rmary, United Kingdom.